Nanobiotix S.A./€NANO

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Nanobiotix S.A.

Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.

Ticker

€NANO
Sector

Primary listing

PAR

Employees

108

Nanobiotix S.A. Metrics

BasicAdvanced
€820M
-
-€1.08
-
-

Bulls say / Bears say

Nanobiotix successfully dosed the first patient in the Johnson & Johnson–sponsored CONVERGE randomized Phase II trial for Stage 3 unresectable non-small cell lung cancer, demonstrating progress in expanding NBTXR3’s therapeutic pipeline beyond pancreatic and head and neck cancers. (BioSpace)
The March 2025 amendment to the global licensing agreement with Janssen Pharmaceutica allocates nearly all cost responsibilities for the pivotal NANORAY-312 Phase III head and neck cancer trial to J&J, extending Nanobiotix’s cash visibility to mid-2026 and materially lowering its R&D burn rate. (The Pharma Letter)
European health authorities formally reclassified NBTXR3 from a medical device to a medicinal product in July 2025, harmonizing its regulatory status with the US and simplifying future global filings under unified drug regulations. (The Pharma Letter)
As of June 30, 2025, Nanobiotix held only €28.8 million in cash and equivalents, projecting operational runway into mid-2026 and warning that existing funds are insufficient to cover the next 12 months without additional financing. (Nanobiotix IR)
The apparent reduction in net loss to €5.4 million in H1 2025 was driven primarily by a €21.2 million non-cash revenue recognition from the J&J licensing amendment, potentially obscuring underlying operational performance. (Nanobiotix IR)
The licensing amendment also released Johnson & Johnson from select future milestone payments, capping Nanobiotix’s potential upside and introducing uncertainty around the realization of anticipated milestone revenues. (The Pharma Letter)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €NANO

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs